(NASDAQ: INAB) In8bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.67%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.32%.
In8bio's earnings in 2025 is -$27,425,000.On average, 2 Wall Street analysts forecast INAB's earnings for 2025 to be -$16,355,124, with the lowest INAB earnings forecast at -$17,263,742, and the highest INAB earnings forecast at -$15,446,506. On average, 2 Wall Street analysts forecast INAB's earnings for 2026 to be -$16,809,584, with the lowest INAB earnings forecast at -$17,263,742, and the highest INAB earnings forecast at -$16,355,124.
In 2028, INAB is forecast to generate $49,021,197 in earnings, with the lowest earnings forecast at $49,021,197 and the highest earnings forecast at $49,021,197.